Anlotinib is an orally administered multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling, which targets receptor tyrosine kinases VEGFR1/2/3, epidermal growth factor receptor (EGFR), fibroblast growth factor receptor 1 to 4, platelet‐derived growth, factor receptor α and β, and stem cell factor receptor. The gene discussed is FLT1; the disease is neoplasm.